Factsheet for health professionals on gonorrhoea
Last reviewed/updated: 16 November 2026
Disclaimer: The information contained in this factsheet is intended for the purpose of general information and should not substitute individual expert advice or judgement of healthcare professionals.
Gonorrhoea is a sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a Gram-negative diplococcus that exclusively infects humans. It primarily affects the urogenital tract but may also infect the rectum, pharynx and conjunctiva. Untreated infection can result in pelvic inflammatory disease, infertility, ectopic pregnancy, epididymitis and disseminated gonococcal infection. A major public health concern is the pathogen’s capacity to develop resistance to antimicrobials, threatening effective treatment options.
Case definition
Gonorrhoea is subject to European Union (EU) and European Economic Area (EEA) epidemiological surveillance. Member States report cases to the European Centre for Disease Prevention and Control (ECDC) on an annual basis according to the case definition established in Commission Implementing Regulation (EU) 2026/2097. If it is not possible to use the EU 2026 case definition, prior versions of the EU case definition or national case definitions may be accepted.
The EU 2026 case definition (applicaple from July 2028)* is as follows:
Gonococcal infection
Clinical criteria
Any person with at least one of the following eleven:
-
Urethritis,
-
Acute salpingitis,
-
Pelvic inflammatory disease,
-
Cervicitis,
-
Epididymitis,
-
Proctitis,
-
Pharyngitis,
-
Arthritis,
-
Purulent conjunctivitis,
-
Perihepatitis,
-
Bartholinitis.
OR
Any newborn child with conjunctivitis.
Laboratory criteria
At least one of the following three:
-
Isolation of Neisseria gonorrhoeae from a clinical specimen
-
Detection of Neisseria gonorrhoeae nucleic acid in a clinical specimen
-
Microscopic detection of intracellular Gram-negative diplococci in a urethral specimen from a male.
Epidemiological criteria
An epidemiological link by human-to-human transmission (sexual contact or vertical transmission).
Case classification:
-
Possible case: NA
-
Probable case: Any person meeting the clinical criteria with an epidemiological link.
-
Confirmed case: Any person meeting the laboratory criteria.
Antimicrobial resistance
For cases ascertained by culture, the results of antimicrobial susceptibility tests shall be reported according to the methods and criteria agreed between the ECDC and the Member States as specified in the ECDC reporting protocol for gonococcal antimicrobial resistance surveillance, which is available to participating Member States.
Cases of possible or confirmed Neisseria gonorrhoeae treatment failure shall be reported to ECDC in accordance with the most current case definitions and following the instructions in the ‘Response plan to control and manage the threat of multi- and extensively drug-resistant gonorrhoea in Europe’ (https://www.ecdc.europa.eu) through the European surveillance portal for infectious diseases (EpiPulse).
The pathogen
Gonorrhoea is caused by Neisseria gonorrhoeae (also known as gonococcus), a Gram-negative diplococcus bacterium that exclusively infects humans [1]. It is closely related to Neisseria meningitidis, but phenotypically distinct [2].
N. gonorrhoeae primarily colonises the mucosal epithelium of the urogenital tract but can also adhere to the mucosa of the rectum, pharynx, and conjunctiva [2,3]. Its pathogenicity is attributed to several virulence factors [2]:
-
Type IV pili, which facilitate attachment to host cells and contribute immune evasion through antigenic variation.
-
Lipooligosaccharides (LOS), which trigger inflammatory responses and contribute to immune evasion.
-
Outer Membrane Proteins (Opa proteins), which mediate invasion of epithelial cells.
-
IgA protease, which cleaves human IgA1 and may contribute to immune evasion.
A defining characteristic of N. gonorrhoeae is its immune evasion through antigenic and phase variation [2]. These mechanisms allow for repeated infections and hinder long-lasting natural immunity [1].
Over recent decades, N. gonorrhoeae has acquired resistance to multiple classes of antibiotics, likely due to its dynamic genome and propensity for horizontal gene transfer [2]. Many gonococcal strains have developed resistance to most antimicrobials used for treatment, including macrolides, sulfonamides, penicillins, tetracyclines and fluoroquinolones [3,4]. This leaves extended-spectrum cephalosporins as the main remaining treatment option in many settings, although instances of treatment failure and resistance to these therapies have also been observed [4,5].
Resistance-associated genes and mutations in N. gonorrhoeae that correlate with reduced susceptibility to antibiotics include [6-8]:
-
Penicillin-Binding Proteins (PBPs): Mutations in genes encoding PBPs, such as penA, are associated with reduced susceptibility to beta-lactam antibiotics.
-
Efflux Pumps: Genetic variations in regulatory genes such as the mtrR gene, can increase expression of efflux pump systems, resulting in increased antibiotic export from bacterial cells.
-
Ribosomal Mutations: Changes in ribosomal RNA genes, including 23S rRNA, can confer resistance to macrolides like azithromycin.
-
DNA replication enzyme modifications: Mutations in these gyrA and parC genes, encoding DNA gyrase and topoisomerase IV, are linked to fluoroquinolone resistance.
-
Acquisition of resistance: Horizontal gene transfer can introduce resistance genes, such as tetM, which confers resistance to tetracycline.
Clinical features and sequelae
Gonorrhoea has a broad range of clinical presentations which include urogenital, rectal, oropharyngeal and conjunctival infections [2].
Urogenital infections
- Males
Among males, most urogenital infections are symptomatic, with asymptomatic infections only occurring in a minority (≤ 10%) [9]. Typical symptoms include urethral discharge and dysuria, usually presenting around two to five days after infection [3]. Complications of untreated infections include epididymitis, orchitis, prostatitis and reduced fertility in severe or prolonged infections [9].
- Females
At least 50% of endocervical infections in females are asymptomatic [9]. When symptoms occur, they typically show within 10 days of infection [1,3]. This longer incubation period compared to males may be due to the presentation of less overt symptoms in females [2]. These symptoms usually include increased or altered cervical discharge, dysuria and sometimes intermenstrual bleeding or menorrhagia [2,3]. Abdominal or pelvic pain can indicate ascending infection, which could lead to pelvic inflammatory disease (PID), including endometritis and salpingitis [3]. These could eventually result in long term sequelae such as ectopic pregnancy and infertility [1,9].
Rectal infections
Rectal infections are frequently reported in gay, bisexual and other men who have sex with men [10]. These infections are often asymptomatic, but when symptoms occur they may include rectal pain, bleeding, pruritus and discharge or tenesmus [3,9].
In females, rectal infection may occur without reported anal intercourse, possibly through autoinoculation from infected genital secretions [3].
Pharyngeal infections
Over 90% of pharyngeal infections are asymptomatic [1,9]. When present, symptoms typically include pharyngitis or tonsillitis [9].
Conjunctival infections
Conjunctival infections can occur via autoinoculation of infected secretions of another site or through vertical transmission in neonates [2,3,9]. Symptoms include eyelid swelling and ocular discharge, as well as photophobia and corneal ulceration if untreated [1,3].
Disseminated gonococcal infection (DGI)
DGI results from gonococcal bacteraemia and occurs in less than 3% of untreated infections [3]. It may manifest with fever, dermatitis, tenosynovitis, arthralgia, or acute arthritis, or a combination of these [9].
Epidemiology
Gonorrhoea is one of the most common bacterial STIs globally. The World Health Organization (WHO) estimated approximately 82.4 million (47.7 million–130.4 million) new cases among people aged 15-49 years in 2020 [11]. Among gay, bisexual and other men who have sex with men globally, a meta-analysis estimated the pooled prevalence of gonorrhoea to be 9.3% (95% CI 7.7–11.1) between 2011 and 2022 [12].
In the EU/EEA, gonorrhoea is the second most frequently reported bacterial STI after chlamydia. Overall, surveillance data indicates that notification rates have increased substantially since 2015. Case notification rates vary considerably across EU/EEA countries, ranging from less than two cases per 100 000 population to more than 100 cases per 100 000 population [13]. This could reflect differences in epidemiology or heterogeneity in testing strategies, laboratory methods and surveillance systems.
Age-specific rates for women are typically highest among those aged 20−24 years, and for men among those aged 25−34 years [13]. Notification rates are consistently higher among men, explained by the burden of gonorrhoea infections in gay, bisexual and other men who have sex with men [12]. The ECDC estimated a pooled prevalence of 10.5% (95% CI 6.9-14.0) in gay, bisexual and other men who have sex with men attending STI clinics [14].
For the most recent summary of epidemiological data in the EU/EEA and reporting countries please refer to the latest Annual Epidemiological Report [15].
Antimicrobial resistance (AMR)
The WHO Global Gonococcal Antimicrobial Surveillance Programme (GASP) indicates that most participating countries reported resistance to ciprofloxacin and azithromycin (98.7% and 87.9% of countries, respectively) between 2019-2022, and decreased susceptibility or resistance to ceftriaxone (38.7% of countries) [16]. Gonococcal AMR distribution varies significantly across the globe, with regional variation in circulating strains, antimicrobial use and surveillance capacity. Surveillance coverage remains limited in Central America and the Caribbean, Eastern Europe, and the WHO African, Eastern Mediterranean, and South-East Asia regions [16]. Nevertheless, the emergence and spread of AMR strains have historically been linked with countries in the WHO Western Pacific and South-East Asia Regions [4]
In the EU/EEA, surveillance through the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) has documented substantial geographical variation in resistance patterns with high levels of ciprofloxacin resistance, ongoing detection of azithromycin resistance, and isolates with reduced susceptibility to extended-spectrum cephalosporins [17]. Resistance is often reported among gay, bisexual and other men who have sex with men and linked to interconnected sexual networks and international travel [5].
Transmission
Transmission of N. gonorrhoeae occurs via sexual contact including oral, anal or vaginal sex in both symptomatic and asymptomatic individuals [1]. Vertical transmission may occur during childbirth through contact with infected genital secretions [1].
Efficiency of transmission is dependent on the site of infection, the site of exposure and the frequency of exposure [2,18]. The risk of transmission can increase with condomless sex, having new sexual partners and multiple concurrent relationships, as well as through practices such as ‘chemsex’ (i.e. the use of specific psychoactive substances to enhance sexual experiences) [13].
Surveillance data reported to ECDC has indicated that the most common transmission mode among cases where this variable is reported is in men who had engaged in sexual contact with other men [13]. This could be explained by an increased frequency of sexual behaviour associated with increased risk of STI transmission, or due to increased testing among this population (e.g. in the context of HIV care or upon enrolment in and follow-up for pre-exposure prophylaxis (PrEP) for HIV) [19].
Diagnostics
Symptoms of gonococcal infections are non-specific and not sufficient for diagnosis. Therefore, a diagnosis requires laboratory confirmation.
Nucleic acid amplification tests (NAATs)
Validated NAATs are recommended for diagnostic testing because of their high sensitivity and specificity. Specimens should be collected from relevant anatomical sites according to sexual history and clinical presentation. The recommended specimens include [9]:
-
Males: first-void urine.
-
Females: vulvo-vaginal swabs, including self-collected swabs.
-
Rectal and pharyngeal swabs only when indicated.
Culture
Following a positive NAAT result, culture specimens should be collected as soon as possible and, where feasible, before treatment is initiated, to support antimicrobial-susceptibility testing and surveillance [9].
Microscopy
Microscopic identification of gonococcus can be useful for rapid diagnosis in symptomatic patients, in particular symptomatic men with urethral discharge. However, it is not recommended for testing asymptomatic samples from urogenital, rectal or oropharyngeal sites [9,20].
Whole Genome Sequencing (WGS)
WGS is increasingly used to identify genetic determinants of resistance and to support molecular epidemiological investigations of outbreaks and transmission networks [6,17].
Point-of-care tests
Molecular point-of-care platforms may enable rapid, multiplex detection of N. gonorrhoeae and other STI pathogens from a single specimen. Some emerging molecular approaches may also detect selected antimicrobial-resistance markers, but these do not replace culture-based antimicrobial-susceptibility testing [21].
Case management and treatment
Warning: ECDC is not an authority on clinical management and should not give advice in this area.
The purpose of case management and treatment of gonorrhoea infections includes the prevention of complications and reduction of onward transmission. This also helps curb antimicrobial resistance in the pathogen.
Upon a positive NAAT diagnostic test, a culture should be performed for AMR testing before initiating antibiotic treatment [9]. The 2020 European guidelines for the treatment of gonorrhoea in adults recommends:
-
high-dose ceftriaxone and azithromycin (ceftriaxone 1 g plus azithromycin 2 g);
OR
-
ceftriaxone 1 g monotherapy only in well-controlled settings for uncomplicated gonorrhoea when the antimicrobial susceptibility is unknown [9].
A test of cure (TOC) is recommended in all cases to ensure the infection was eradicated and to identify emerging antimicrobial resistance [9]. In the case of treatment failure of the recommended treatment regimen, additional data should be collected (e.g. clinical and laboratory data, exclusion of reinfection, whole genome sequencing of pre-treatment and post-treatment gonococcal isolates), and the case should be reported to ECDC EpiPulse [22]. Please refer to European clinical guidelines for further information.
Prompt diagnosis and treatment are important for successful case management. Patients should receive instructions on treatment administration, partner notification and partner treatment management [9]. It is recommended that people with a confirmed gonorrhoea diagnosis are offered testing for other STIs, and that they are advised to abstain from sexual contact for 14 days after completing treatment [9].
Changing treatment guidelines
New therapeutic options include zoliflodacin and gepotidacin [23,24]. Access to these new drugs is facilitated by established mechanisms through compassionate-use pathways, ensuring preparedness in the cases where treatment options currently recommended in clinical guidelines are ineffective or unavailable.
Prevention
Prevention for all sexually transmitted infections comprises primary prevention, which aims to reduce the risk of acquiring infections, and secondary prevention, which focuses on early detection and treatment to prevent complications and further transmission.
A key aspect of both primary and secondary prevention of STIs is comprehensive sex education in schools and provision of sexual health information by healthcare providers. This includes knowledge of safe sexual practices, facilitating access to barrier protection and testing services, as well as integrating STI prevention into routine care pathways wherever feasible [20].
A large proportion of STIs are asymptomatic and natural immunity is short-lived, meaning individuals are often unaware of their infection status and can unknowingly transmit the infection and easily become (re-)infected.
Primary prevention: reducing risk of STI acquisition
Primary prevention strategies aim to reduce the likelihood of infection during sexual contact. Key measures include:
-
Promotion and provision of barrier protection: Consistent and correct use of condoms, internal condoms and dental dams significantly lowers transmission risk. Access to these should be promoted.
-
Sexual health education and counselling: Counselling should be tailored to individual needs to support informed decision-making and safer sexual practices. This may include discussion of factors associated with increased STI risk, including multiple or concurrent sexual relationships, mixing across sexual networks and engaging in activities that increase susceptibility to transmission.
- Risk reduction during symptomatic periods: In the presence of lesions or symptoms including ulcers, discharge, and rashes, individuals should be advised to avoid sexual contact or use appropriate protective measures until symptoms are managed, as these are associated with higher infectiousness.
-
Awareness of reinfection and ongoing prevention needs: Since most STIs do not confer lasting immunity after infection, individuals should be aware of the risk of re-infection and encouraged to maintain preventive behaviours post-treatment.
Secondary prevention: early detection and treatment
Secondary prevention aims to shorten the infectious period and prevent complications. Key actions include:
-
Timely healthcare-seeking: Early recognition of symptoms and prompt access to testing and treatment are important. Accessible and integrated services including free or low cost, on demand testing is recommended.
-
Testing: Regular testing in populations at increased risk of infection according to evidence-based national or international guidelines is recommended, as well as provider-initiated testing based on sexual history and assessed risk facilitates early detection.
-
Effective treatment: Completed course of evidence-based regimens reduce individual morbidity, risk of complications, and community transmission.
-
Partner notification and management: Contact tracing and partner management approaches are useful to prevent reinfection and interrupt transmission chains.
National strategy
Public health measures concerning gonorrhoea transmission are highly focused on the increasing AMR of gonococcus globally and across the EU/EEA. Considering the interconnected nature of regional sexual networks, strengthening antimicrobial surveillance of N. gonorrhoeae in Europe is a priority [25].
For this purpose, the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) provides EU/EEA countries with access to quality-assured antimicrobial susceptibility testing (AST), regular external quality assessment, expert advice and laboratory training to strengthen capacity against the threat of AMR [25]. It is crucial for EU/EEA countries to report data to EpiPulse Cases to understand transmission patterns, resistance patterns, as well as key populations at risk. Importantly, this includes reporting cases of suspected treatment failure, ensuring that these cases are followed up and monitored to detect any emergence of resistant strains. This supports monitoring whether treatment guidelines remain effective for circulating strains [22].
ECDC recommends that EU/EEA countries maintain a national strategy and response plan for the control of multi- and extensively drug-resistant gonorrhoea, including [25]:
- access to primary prevention interventions for individuals and groups at increased risk of infection and information on the increasing occurrence of AMR;
- implementation of evidence-based case management guidelines for each setting in which gonorrhoea may be diagnosed
- access to accurate diagnostics and participation in Euro-GASP;
- robust surveillance of diagnosed infections and associated AMR patterns, as well as investigation and reporting of treatment failures;
- a plan for monitoring and evaluation of the national strategy’s effectiveness.
Doxycycline post-exposure prophylaxis (doxyPEP)
DoxyPEP is a single 200 mg dose of doxycycline taken within 24−72 hours after sexual exposure, for the prevention of bacterial STIs [26]. Evidence indicates that doxyPEP is less effective against gonorrhoea than against chlamydia and syphilis [26]. The use of doxyPEP raises concerns about antimicrobial resistance and its use is not recommended as a population-level intervention for gonorrhoea prevention [26].
Vaccination
Although several vaccine candidates remain under clinical investigation, there is currently no licensed gonorrhoea vaccine in the EU/EEA [27].
Observational studies have suggested that the four-component meningococcal group B vaccine (4CMenB) may provide partial cross-protection against gonorrhoea infections [28-30]. Based on this evidence, the UK and Galicia, Spain have introduced targeted 4CMenB vaccination for people at elevated risk in 2025 [29]. However, recent randomised trials in gay, bisexual and other men who have sex with men at high risk of infection did not demonstrate statistically significant protection against gonorrhoea [31,32]. The effectiveness of this vaccination strategy therefore remains uncertain, and further evidence from programme monitoring and studies in different populations will be important [29].
Advice to travellers
Disclaimer: Travel health physicians and travellers should always first consult national travel guidelines and recommendations as the primary source of information.
The introduction and spread of some multidrug-resistant and extensively drug-resistant gonococcal strains into Europe can be linked to people travelling internationally and acquiring these strains through sexual contact before returning to Europe. Travellers should therefore be advised to use protection when having sex with new partners when travelling. They should pack reliable barrier protection and seek testing if they develop symptoms or if sexual activity during their travel posed an increased risk for acquiring N. gonorrhoeae infection.
*The new definition outlined in the factsheet is only applicable from July 2028. Until then the old EU case definition applies.
References
- Holmes KK, Sparling FP, Stamm WE, Piot P, Stamm WE. Sexually Transmitted Diseases. New York, USA, UNITED STATES: McGraw-Hill Professional Publishing; 2008.
- Quillin SJ, Seifert HS. Neisseria gonorrhoeae host adaptation and pathogenesis. Nature Reviews Microbiology. 2018 2018/04/01;16(4):226-40. Available at: https://doi.org/10.1038/nrmicro.2017.169
- Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 9th ed. Philadelphia: Elsevier; 2020.
- Unemo M, Shafer William M. Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future. Clinical Microbiology Reviews. 2014;27(3):587-613. Available at: https://doi.org/10.1128/cmr.00010-14
- European Centre for Disease Prevention and Control. Risk assessment – Upsurge in ceftriaxone-resistant Neisseria gonorrhoeae with evidence of domestic transmission in the EU/EEA and the UK. 16 July 2026. ECDC: Stockholm; 2026.
- Eyre DW, De Silva D, Cole K, Peters J, Cole MJ, Grad YH, et al. WGS to predict antibiotic MICs for Neisseria gonorrhoeae. Journal of Antimicrobial Chemotherapy. 2017;72(7):1937-47. Available at: https://doi.org/10.1093/jac/dkx067
- Sánchez-Busó L, Yeats CA, Taylor B, Goater RJ, Underwood A, Abudahab K, et al. A community-driven resource for genomic epidemiology and antimicrobial resistance prediction of Neisseria gonorrhoeae at Pathogenwatch. Genome Medicine. 2021 2021/04/19;13(1):61. Available at: https://doi.org/10.1186/s13073-021-00858-2
- Mendes AC, de Souza RP, Bahia D. The frequency of mutations in the penA, mtrR, gyrA and parC genes of Neisseria gonorrhoeae, the presence of tetM gene and antibiotic resistance/susceptibility: a systematic review and meta-analyses. Frontiers in Microbiology. 2025;Volume 15 - 2024 Available at: https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1414330
- Unemo M, Ross J, Serwin A, Gomberg M, Cusini M, Jensen J. 2020 European guideline for the diagnosis and treatment of gonorrhoea in adults. International Journal of STD & AIDS. 2020;0(0):0956462420949126. Available at: https://journals.sagepub.com/doi/abs/10.1177/0956462420949126
- Chidiac O, AlMukdad S, Harfouche M, Harding-Esch E, Abu-Raddad LJ. Epidemiology of gonorrhoea: systematic review, meta-analyses, and meta-regressions, World Health Organization European Region, 1949 to 2021. Eurosurveillance. 2024;29(9):2300226.
- World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016–2021: actions for impact. Geneva. 2021. Available at: https://iris.who.int/handle/10665/341412)
- Davies EP, Tsuboi M, Evans J, Rowley J, Korenromp EL, Clayton T, et al. A global meta-analysis of gonorrhoea and chlamydia prevalence among men who have sex with men from 2000 to 2022. International Journal of STD & AIDS. 2025 2025/07/01;36(8):611-21. Available at: https://doi.org/10.1177/09564624251333489
- European Centre for Disease Prevention and Control. Gonorrhoea. In: ECDC. Annual epidemiological report for 2024. Stockholm: ECDC; 2026.
- European Centre for Disease Prevention and Control. A systematic review and meta-analysis of the prevalence of chlamydia, gonorrhoea, trichomoniasis and syphilis in Europe. Stockholm: ECDC; 2024.
- European Centre for Disease Prevention and Control (ECDC). Annual Epidemiological Reports (AERs). Stockholm: ECDC; 2025. Available at: https://www.ecdc.europa.eu/en/publications-data/monitoring/all-annual-epidemiological-reports.
- Unemo M, Lahra MM, Cole MJ, Marcano Zamora D, Jacobsson S, Galarza P, et al. WHO global gonococcal antimicrobial surveillance programmes, 2019-22: a retrospective observational study. The Lancet Microbe. 2025;6(10) Available at: https://doi.org/10.1016/j.lanmic.2025.101181
- European Centre for Disease Prevention and Control. Gonococcal antimicrobial susceptibility surveillance in the European Union/European Economic Area, 2024. Stockholm: ECDC; 2026.
- Hui B, Fairley CK, Chen M, Grulich A, Hocking J, Prestage G, et al. Oral and anal sex are key to sustaining gonorrhoea at endemic levels in MSM populations: a mathematical model. Sexually Transmitted Infections. 2015;91(5):365-9. Available at: https://sti.bmj.com/content/sextrans/91/5/365.full.pdf
- European Centre for Disease Prevention and Control (ECDC). Gonorrhoea. In: ECDC. Annual epidemiological report for 2023. Stockholm: ECDC, 2025
- Organization WH. The diagnostics landscape for sexually transmitted infections: World Health Organization; 2023.
- Organization WH. Laboratory and point-of-care diagnostic testing for sexually transmitted infections, including HIV. Geneva: World Health Organization; 2023.
- European Centre for Disease Prevention and Control (ECDC). Response plan to control and manage the threat of multi- and extensively drug-resistant gonorrhoea in Europe – Indicator monitoring 2019. Stockholm: ECDC; 2021.
- Luckey A, Balasegaram M, Barbee LA, Batteiger TA, Broadhurst H, Cohen SE, et al. Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial. The Lancet. 2026;407(10524):147-60. Available at: https://doi.org/10.1016/S0140-6736(25)01953-1
- Ross JDC, Wilson J, Workowski KA, Taylor SN, Lewis DA, Gatsi S, et al. Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study. The Lancet. 2025 2025/05/03/;405(10489):1608-20. Available at: https://www.sciencedirect.com/science/article/pii/S0140673625006282
- European Centre for Disease Prevention and Control. Response plan to control and manage the threat of multi- and extensively drug-resistant gonorrhoea in Europe – Indicator Monitoring 2023. Stockholm: ECDC; 2026.
- European Centre for Disease Prevention and Control. Public health considerations on the use of doxycycline for post-exposure prophylaxis for bacterial sexually transmitted infections in the EU/EEA. Stockholm: ECDC; 2026.
- GlaxoSmithKline. Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age.: NIH; 2024. Available at: https://clinicaltrials.gov/study/NCT05630859#collaborators-and-investigators.
- Ladhani SN, Mandal S, Mohammed H, Saunders J, Andrews N, Ramsay ME, et al. The United Kingdom meningococcal vaccine (4CMenB) programme against gonorrhoea: A review of the evidence and knowledge gaps. Journal of Infection. 2025 2025/09/01/;91(3):106582. Available at: https://www.sciencedirect.com/science/article/pii/S0163445325001823
- Slesarenko VA, Eskandari S, Semchenko EA, Seib KL. Vaccination for Gonorrhoea: Where Are We Now, and What Comes Next? Drugs. 2026 2026/11/01;86(11):1769-80. Available at: https://doi.org/10.1007/s40265-026-02387-x
- Abara WE, Kirkcaldy RD, Bernstein KT, Galloway E, Learner ER. Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis. J Infect Dis. 2025 Feb 4;231(1):61-70. Available at: https://www.ncbi.nlm.nih.gov/pubmed/39082700
- Seib KL, Donovan B, Jin F, Thng C, Yeung B, Comninos N, et al. Meningococcal B vaccine to prevent Neisseria gonorrhoeae infection. New England Journal of Medicine. 2026
- Thng C, Eskandari S, Jin F, Hughes I, Grulich AE, O'Sullivan M, et al. Efficacy of the meningococcal vaccine against Neisseria gonorrhoeae: a randomised clinical trial (MenGO). NPJ Vaccines. 2026 Apr 22;11(1)